首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   167篇
  免费   10篇
  国内免费   3篇
儿科学   5篇
妇产科学   6篇
基础医学   7篇
口腔科学   1篇
临床医学   11篇
内科学   85篇
皮肤病学   5篇
神经病学   9篇
外科学   34篇
综合类   5篇
预防医学   1篇
药学   7篇
肿瘤学   4篇
  2021年   3篇
  2019年   1篇
  2018年   2篇
  2017年   2篇
  2016年   1篇
  2014年   2篇
  2012年   2篇
  2011年   1篇
  2010年   2篇
  2009年   3篇
  2008年   6篇
  2007年   3篇
  2006年   8篇
  2005年   7篇
  2004年   11篇
  2003年   20篇
  2002年   19篇
  2001年   6篇
  2000年   6篇
  1999年   8篇
  1998年   2篇
  1997年   1篇
  1996年   2篇
  1994年   2篇
  1993年   1篇
  1992年   3篇
  1991年   2篇
  1990年   3篇
  1988年   1篇
  1987年   2篇
  1981年   1篇
  1979年   1篇
  1978年   2篇
  1977年   1篇
  1976年   2篇
  1975年   5篇
  1974年   9篇
  1973年   5篇
  1972年   4篇
  1971年   2篇
  1970年   6篇
  1969年   3篇
  1968年   5篇
  1966年   1篇
  1965年   1篇
排序方式: 共有180条查询结果,搜索用时 15 毫秒
11.

Background

Worldwide approximately 200 million adults undergo major surgery annually, of whom 8 million are estimated to suffer a myocardial injury after noncardiac surgery (MINS). There is currently no trial data informing the management of MINS. Antithrombotic agents such as direct oral anticoagulants might prevent major vascular complications in patients with MINS.

Methods

The Management of Myocardial Injury After Noncardiac Surgery (MANAGE) trial is a large international blinded randomized controlled trial of dabigatran vs placebo in patients who suffered MINS. We used a partial factorial design to also determine the effect of omeprazole vs placebo in reducing upper gastrointestinal bleeding and complications. Both study drugs were initiated in eligible patients within 35 days of suffering MINS and continued for a maximum of 2 years. The primary outcome is a composite of major vascular complications for the dabigatran trial and a composite of upper gastrointestinal complications for the omeprazole trial. We present the rationale and design of the trial and baseline characteristics of enrolled patients.

Results

The trial randomized 1754 patients between January 2013 and July 2017. Patients' mean age was 69.9 years, 51.1% were male, 14.3% had a history of peripheral artery disease, 6.6% had a history of stroke or transient ischemic attack, 12.9% had a previous myocardial infarction, and 26.0% had diabetes. The diagnosis of MINS was on the basis of an isolated ischemic troponin elevation in 80.4% of participants.

Conclusion

MANAGE is the first randomized controlled trial to evaluate a potential treatment of patients who suffered MINS.  相似文献   
12.
Adiponectin is a plasma protein expressed exclusively in adipose tissue. Adiponectin levels are linked to insulin sensitivity, but a direct effect of chronically elevated adiponectin on improved insulin sensitivity has not yet been demonstrated. We identified a dominant mutation in the collagenous domain of adiponectin that elevated circulating adiponectin values in mice by 3-fold. Adiponectinemia raised lipid clearance and lipoprotein lipase activity, and suppressed insulin-mediated endogenous glucose production. The induction of adiponectin during puberty and the sexual dimorphism in adult adiponectin values were preserved in these transgenic animals. As a result of elevated adiponectin, serum PRL values and brown adipose mass both increased. The effects on carbohydrate and lipid metabolism were associated with elevated phosphorylation of 5'-AMP-activated protein kinase in liver and elevated expression of peroxisomal proliferator-activated receptor gamma2, caveolin-1, and mitochondrial markers in white adipose tissue. These studies strongly suggest that increasing endogenous adiponectin levels has direct effects on insulin sensitivity and may induce similar physiological responses as prolonged treatment with peroxisomal proliferator-activated receptor gamma agonists.  相似文献   
13.

Background

Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a widely used form of mechanical circulatory support in patients with refractory cardiogenic shock. A common drawback of this modality is a resultant increase in left ventricular afterload.

Objectives

The purpose of this meta-analysis was to examine the efficacy and safety of left ventricular unloading strategies during VA-ECMO in adult patients with cardiogenic shock.

Methods

The authors performed a systematic search of studies examining left ventricular unloading during VA-ECMO in Medline, EMBASE, and the Cochrane library. The primary outcome was all-cause mortality. Secondary outcomes included limb ischemia, bleeding, need for renal replacement therapy, multiorgan failure, stroke or transient ischemic attack, and hemolysis.

Results

Of 2,221 publications identified, 17 observational studies met the inclusion criteria. In total, outcomes in 3,997 patients were included with 1,696 (42%) receiving a concomitant left ventricular unloading strategy while on VA-ECMO (intra-aortic balloon pump 91.7%, percutaneous ventricular assist device 5.5%, pulmonary vein or transseptal left atrial cannulation 2.8%). There were 2,412 deaths (60%) in the total cohort. Mortality was lower in patients with (54%) versus without (65%) left ventricular unloading while on VA-ECMO (risk ratio: 0.79; 95% confidence interval: 0.72 to 0.87; p < 0.00001). Hemolysis was higher in patients who underwent VA-ECMO with left ventricular unloading. Otherwise, secondary outcomes were not demonstrably different in patients treated with VA-ECMO with versus without left ventricular unloading.

Conclusions

In observational studies, left ventricular unloading was associated with decreased mortality in adult patients with cardiogenic shock treated with VA-ECMO. In the absence of prospective randomized data, left ventricular unloading may be considered for appropriately selected patients undergoing VA-ECMO support.  相似文献   
14.
15.
Type 2 diabetes mellitus results from a complex interaction between nutritional excess and multiple genes. Whereas pancreatic beta-cells normally respond to glucose challenge by rapid insulin release (first phase insulin secretion), there is a loss of this acute response in virtually all of the type 2 diabetes patients with significant fasting hyperglycemia. Our previous studies demonstrated that irreversible intracellular accumulation of a glucose metabolite, protein O-linked N-acetylglucosamine modification (O-GlcNAc), is associated with pancreatic beta-cell apoptosis. In the present study, we show that streptozotocin (STZ), a non-competitive chemical blocker of O-GlcNAcase, induces an insulin secretory defect in isolated rat islet cells. In contrast, transgenic mice with down-regulated glucose to glucosamine metabolism in beta-cells exhibited an enhanced insulin secretion capacity. Interestingly, the STZ blockade of O-GlcNAcase activity is also associated with a growth hormone secretory defect and impairment of intracellular secretory vesicle trafficking. These results provide evidence for the roles of O-GlcNAc in the insulin secretion and possible involvement of O-GlcNAc in general glucose-regulated hormone secretion pathways.  相似文献   
16.
A sensitive, semi-quantitative radioimmunoassay method to screen for elevations of TSH concentration in blood is described. The method requires two 0.32 cm dots of dried blood-impregnated filter paper (equivalent to 3 mul plasma) and a 3-day incubation. Separation of bound and free is obtained using polyethylene glycol. The method can recognize TSH concentrations as low as 22 muU/ml using a highly sensitive antiserum developed by one of us (AFP). TSH in dried cord and newborn blood from 4 infants with congenital hypothyroidism was clearly higher than in normal infants. The method is suitable for use in a newborn screening program to confirm the suspicion of primary hypothyroidism in specimens with low T4 concentrations.  相似文献   
17.
18.
Canadian Journal of Anesthesia/Journal canadien d'anesthésie -  相似文献   
19.
Parlow  Joel  Milne  Brian  Gilron  Ian  Shore  Debbie  Orr  Elizabeth 《Journal canadien d'anesthésie》2008,55(1):4718961-4718962
Canadian Journal of Anesthesia/Journal canadien d'anesthésie -  相似文献   
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号